Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Breast Cancer
In brief
The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.
Key facts
- Study ID
- NCT01276704
- Run by
- Carol Fabian, MD
- People needed
- 180
- Starts
- 2011-01-01
- Expected to finish
- 2017-07-01
- Last updated by the study team
- 2023-09-21
Who can join
Age: 21 and older, up to 49. Sex: female. Healthy volunteers: accepted.
Where it is running
- University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
- Northwestern University Medical Center — Chicago, Illinois, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Ohio State Unviersity Medical Center — Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States
- University of Washington — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.